Patricia LoRusso, DO, PhD, professor of medicine and associate director of Innovative Medicine at Yale Cancer Center, discusses the key questions that still remain regarding combination and sequencing with PARP inhibitors.
Patricia LoRusso, DO, PhD
Advertisement
Articles by Patricia LoRusso, DO, PhD
Advertisement
Latest Updated Articles
Questions That Remain Regarding Combination, Sequencing With PARP InhibitorsPublished: September 25th 2016 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
